scispace - formally typeset
M

Matija Tomšič

Researcher at University of Ljubljana

Publications -  196
Citations -  3973

Matija Tomšič is an academic researcher from University of Ljubljana. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 28, co-authored 163 publications receiving 3285 citations. Previous affiliations of Matija Tomšič include Academy of Sciences of the Czech Republic & Ljubljana University Medical Centre.

Papers
More filters
Journal ArticleDOI

Melting of Self-Assembled Columnar Aggregates Formed in Aqueous Solutions of Deoxy- and Guanosine 5′-Monophosphate

TL;DR: In this paper, the self-assembling properties of aqueous solutions of deoxy- and guanosine 5'-monophospate (dGMP and GMP) in the pretransitional region of the I-Ch phase transition was investigated by dynamic light scattering (DLS) and small-angle X-ray scattering (SAXS).
Journal ArticleDOI

IgA vasculitis in adults: few certainties and many uncertainties.

TL;DR: Both a childhood and an adult onset of IgAV incidence rates are estimated and an increased risk of hypertension and chronic kidney disease in patients with IgAV is reported, compared with age-matched and sex-matched controls based on retrospective data over a 12-year period extracted from a primary care database in the UK.
Journal ArticleDOI

From Active to Non-active Giant Cell Arteritis: Longitudinal Monitoring of Patients on Glucocorticoid Therapy in Combination With Leflunomide

TL;DR: Leukocyte subsets, expression of neutrophil surface adhesion molecules, and serum analytes in therapy-naïve patients with active giant cell arteritis were monitored to identify candidate biomarkers that could be used to monitor disease activity and predict an increased risk of a relapse.
Journal ArticleDOI

Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: A single-center, open-label study

TL;DR: In this article , the role of leflunomide as a steroid-sparing agent in GCA was evaluated in a prospective open-label study with 215 patients diagnosed with GCA between July 2014 and August 2020.
Journal Article

ADORA2A Polymorphisms Influence Methotrexate Adverse Events in Rheumatoid Arthritis.

TL;DR: Polymorphisms in the ADORA2A gene may influence methotrexate treatment response and may be considered as a potential biomarker for methotRexate treatment in rheumatoid arthritis.